The euphoria has powered a surge in new listings. More than 180 companies raised over $50 billion in IPOs in the U.S. in the first three quarters, putting 2018 on track to be the busiest year for new issuance by both measures since 2014, according to Dealogic. That year, IPOs jumped thanks in part to Alibaba Group Holding Ltd.’s $25 billion offering as well as a surge in biotech companies going public.
This past Wednesday, online-survey provider SurveyMonkey’s parent SVMK Inc., which hasn’t had a profitable year and posted a $24 million net loss in 2017, jumped more than 40% in its debut after pricing above its targeted range. Shares of Tilray Inc. an unprofitable Canadian cannabis retailer that is one of the few pot companies listed in the U.S., soared more than 800% since its Nasdaq debut this summer.
Meanwhile, biotechnology company Solid Biosciences Inc., which hadn’t yet generated revenue—let alone earnings—informed the market ahead of its January IPO that one of its clinical trials was put on hold. Investors ignored that potential red flag and the company raised $144 million. Its stock has nearly tripled since then.
It’s a good time to list a company. Interest rates are not so high as to inhibit risk appetites. Financial conditions are still accommodative. The world’s largest economy is “almost too good to be true” in the words of the Fed chair and investors are chasing growth because the returns on value have been lacklustre.Click HERE to subscribe to Fuller Treacy Money Back to top